• News

"In Ileal Crohn's Disease, Cell Signature Correlates With Resistance To Therapy" - Marilynn Larkin

  • MD Alert
  • New York, NY
  • (September 03, 2019)

A cell signature present at ileal Crohn's disease diagnosis is associated with resistance to standard anti-TNF therapy, according to researchers at the Icahn School of Medicine at Mount Sinai and published in Cell. To investigate whether cellular heterogeneity is involved in treatment resistance, the team analyzed biopsy samples of both inflamed and uninflamed iCD lesions upon removal from 15 patients. “Importantly, we found that the presence of the GIMATS module in patients was independent of pathology severity, disease duration, and systemic markers of inflammation,” said Miriam Merad, MD, PhD, Director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai. She added, “The take-home message is that current diagnostic assays - clinical and histological - are not informative enough and there is a great need for more granular cellular and molecular classification of disease to guide therapeutic strategies.”

— Miriam Merad, MD, PhD, Professor, Medicine, Hematology and Medical Oncology, Oncological Sciences, Director, Precision Immunology Institute, Co-Director, Cancer Immunology Program, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, Mount Sinai Health System

Learn more